RayKnowChina Research Map
Shortlist

Lanzhou

First Hospital of Lanzhou University

兰州大学第一医院

Listed for 18 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Hospital of Lanzhou University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌3 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌1 paper led
  3. Hepatocellular carcinoma肝细胞癌46 papers led
  4. Stomach cancer胃癌45 papers led
  5. Osteosarcoma骨肉瘤3 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  7. Ewing sarcoma尤文肉瘤0 papers led
  8. Multiple myeloma多发性骨髓瘤2 papers led
  9. Haemophilia A血友病 A1 paper led
  10. Hepatic echinococcosis肝包虫病1 paper led
  11. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
  12. Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
  13. Fabry disease法布雷病1 paper led
  14. Behçet disease白塞病0 papers led
  15. IgA nephropathyIgA 肾病0 papers led
  16. Osteogenesis imperfecta成骨不全症1 paper led
  17. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  18. Hereditary angioedema遗传性血管性水肿0 papers led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 222025

1 hospital in Lanzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapy
Departments in papersENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 1 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.03%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

3 hospitals in Lanzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomics
Departments in papersGastroenterology / hepatology
Papers it led1
  1. Identification of immunophenotypes in esophageal squamous cell carcinoma based on immune gene sets.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
More papers found outside PubMed (not counted)1
  1. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 46 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
46
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 7720212022: 6620222023: 101020232024: 8820242025: 15152025

2 hospitals in Lanzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2025-01
    Registry
    NCT06779461

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBengbu, Guangzhou, Lanzhou, Nanjing, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionSurgery & liver transplant
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncology
Papers it led46
  1. Automated detection of small hepatocellular carcinoma in cirrhotic livers: applying deep learning to Gd-EOB-DTPA-enhanced MRI.2025Abdominal radiology (New York)
  2. Establishment and characterization of CHC-X1: the third human combined hepatocellular-cholangiocarcinoma cell line.2025BMC cancerFree full text
  3. KAT7-acetylated YBX1 promotes hepatocellular carcinoma proliferation by reprogramming nucleotide metabolism.2025BMC cancerFree full text
  4. Deep learning-based MRI model for predicting P53-mutated hepatocellular carcinoma.2025BMC medical imagingFree full text
  5. Multi-omics pan-cancer analysis of monocyte to macrophage differentiation-associated (MMD) and its significance in hepatocellular carcinoma.2025Cancer biomarkers : section A of Disease markersFree full text
  6. Prediction Model for Familial Aggregated HBV-Associated Hepatocellular Carcinoma Based on Serum Biomarkers.2025Cancer reports (Hoboken, N.J.)Free full text
  7. Single-Cell Transcriptional Analysis Reveals the Mechanism of AZD6738 in HCC Immunotherapy via EZH2 Targeting.2025Drug design, development and therapyFree full text
  8. Advances in multi-omics studies of microvascular invasion in hepatocellular carcinoma.2025European journal of medical researchFree full text
  9. Patterns and outcomes of early and late recurrence after hepatectomy for hepatocellular carcinoma with microvascular invasion: a multicenter study in China.2025Hepatology international
  10. LI-RADS CT and MRI Major Feature Association with Vessels Encapsulating Tumor Clusters Pattern and Recurrence in Hepatocellular Carcinoma: A Preliminary Study.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  11. Diagnostic performance based on MRI for preoperative of vessels encapsulating tumor clusters in hepatocellular carcinoma: a systematic review and meta-analysis.2025La Radiologia medica
  12. Unravelling the Role of PANoptosis in Liver Diseases: Mechanisms and Therapeutic Implications.2025Liver international : official journal of the International Association for the Study of the Liver
  13. Pharmacokinetic, biodistribution, safety and efficacy studies of borophenylalanine (BPA) in BNCT in hepatocellular carcinoma cells and tumor-bearing mouse model.2025Scientific reportsFree full text
  14. A reliable prognostic model for hepatocellular carcinoma using neutrophil extracellular traps and immune related genes.2025Scientific reportsFree full text
  15. Advances in imaging techniques for tumor microenvironment evaluation in hepatocellular carcinoma.2025World journal of gastroenterologyFree full text
  16. A nomogram for preoperative prediction of vessels encapsulating tumor clusters (VETC) pattern and prognosis of hepatocellular carcinoma.2024American journal of surgery
  17. Evaluating the potential of off-the-shelf engineered mesenchymal stem cells for targeted Hepatocellular Carcinoma treatment: A multisite proof-of-concept study.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  18. Identifying the predictive role and the related drugs of oxidative stress genes in the hepatocellular carcinoma.2024Cancer reports (Hoboken, N.J.)Free full text
  19. The prognostic value of vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma: a systematic review and meta-analysis.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  20. Research progresses of imaging studies on preoperative prediction of microvascular invasion of hepatocellular carcinoma.2024Clinical hemorheology and microcirculation
  21. Clinical application of dual-layer spectral CT multi-parameter feature to predict microvascular invasion in hepatocellular carcinoma.2024Clinical hemorheology and microcirculation
  22. Prediction of vessels encapsulating tumor clusters pattern and prognosis of hepatocellular carcinoma based on preoperative gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid magnetic resonance imaging.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  23. Hepatocellular Carcinoma: Prevention, Diagnosis, and Treatment.2024Medical principles and practice : international journal of the Kuwait University, Health Science CentreFree full text
  24. Knockdown of CD44 inhibits proliferation, migration, and invasiveness in hepatocellular carcinoma cells by modulating CXCR4/Wnt/β-Catenin Axis.2023Acta biochimica Polonica
  25. MicroRNA-6838-5p suppresses the self-renewal and metastasis of human liver cancer stem cells through downregulating CBX4 expression and inactivating ERK signaling.2023Biological chemistry
  26. (2E)-1-(2,4,6-Trimethoxyphenyl)-3-(4-chlorophenyl)prop-2-en-1-one, a Chalcone Derivative, Promotes Apoptosis by Suppressing RAS-ERK and AKT/FOXO3a Pathways in Hepatocellular Carcinoma Cells.2023Chemistry & biodiversity
  27. A Nomogram of Magnetic Resonance Imaging for Preoperative Assessment of Microvascular Invasion and Prognosis of Hepatocellular Carcinoma.2023Digestive diseases and sciences
  28. Diagnostic accuracy of circulating-free DNA for the determination of hepatocellular carcinoma: a systematic review and meta-analysis.2023Expert review of molecular diagnostics
  29. Establishment and characterization of a new Chinese hepatocellular carcinoma cell line, Hep-X1.2023Human cell
  30. Tumor cell density dependent IL-8 secretion induces the fluctuation of tregs/CD8 + T cells infiltration in hepatocellular carcinoma: one prompt for the existence of density checkpoint.2023Journal of translational medicineFree full text
  31. CircCPSF6 promotes hepatocellular carcinoma cancer progression by regulating MAP4K4 through sponging miR-145-5p.2023Molecular and cellular probes
  32. FOXP3 and SQSTM1/P62 correlate with prognosis and immune infiltration in hepatocellular carcinoma.2023Pathology, research and practice
  33. BAIAP2L2 is a novel prognostic biomarker related to migration and invasion of HCC and associated with cuprotosis.2023Scientific reportsFree full text
  34. Development and validation of an ECM-related prognostic signature to predict the immune landscape of human hepatocellular carcinoma.2022BMC cancerFree full text
  35. Intercellular communication in the tumour microecosystem: Mediators and therapeutic approaches for hepatocellular carcinoma.2022Biochimica et biophysica acta. Molecular basis of disease
  36. Is Gadoxetic Acid Disodium (Gd-EOB-DTPA)-Enhanced Magnetic Resonance Imaging an Accurate Diagnostic Method for Hepatocellular Carcinoma? A Systematic Review with Meta-Analysis.2022Current medical imaging
  37. LncRNA SNHG7 Promotes the HCC Progression Through miR-122-5p/FOXK2 Axis.2022Digestive diseases and sciences
  38. Heterogeneous matrix stiffness regulates the cancer stem-like cell phenotype in hepatocellular carcinoma.2022Journal of translational medicineFree full text
  39. Efficacy and safety of microwave ablation and radiofrequency ablation in the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.2022MedicineFree full text
  40. N-trans-Feruloyloctopamine Wakes Up BBC3, DDIT3, CDKN1A, and NOXA Signals to Accelerate HCC Cell Apoptosis.2021Analytical cellular pathology (Amsterdam)Free full text
  41. RAP2A promotes apoptosis resistance of hepatocellular carcinoma cells via the mTOR pathway.2021Clinical and experimental medicine
  42. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.2021Frontiers in immunologyFree full text
  43. Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF-κB pathway and regulating transporter mediated drug efflux.2021Journal of ethnopharmacology
  44. A step forward to predict the risk of post-hepatectomy portal hypertension.2021Journal of hepatology
  45. Synchronous double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma: A case report and review of the literature.2021MedicineFree full text
  46. Loss of neuropilin1 inhibits liver cancer stem cells population and blocks metastasis in hepatocellular carcinoma via epithelial-mesenchymal transition.2021Neoplasma
Chinese-language papers (not in the count)5
  1. [Strategies of statins for the prevention and treatment of hepatocellular carcinoma].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Research progress of radiomics in the evaluation of microvascular invasion in hepatocellular carcinoma].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  3. [MicroRNA Methylation in the Diagnosis and Treatment of Hepatocellular Carcinoma].2022Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  4. [Current status and prospects of clinical research on portal hypertension in China].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  5. [Clinical observation of surgical resection combined radiofrequency in patients with CNLC Ⅱa~Ⅲa stage multiple hepatocellular carcinoma].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status4
  1. A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular CarcinomaNot yet recruitingNCT06779461Study sitePhase 3Start 2025-01
  2. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  3. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  4. Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery RecurrenceStatus unknownNCT04213118Study sitePhase 2Start 2020-04

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 45 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.5%.

Papers led
45
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 101020212022: 111120222023: 4420232024: 6620242025: 12122025

3 hospitals in Lanzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06873659

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an

  3. Recruiting
    Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-04
    Registry
    NCT06925243

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou

  4. Recruiting
    Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06949033

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou

  5. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  6. Not yet recruiting
    Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing
    Phase
    Phase 4
    Started
    2026-04
    Registry
    NCT07312370

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteLanzhou

  7. Not yet recruiting
    Recurrence After Gastric and Intestinal Polyp Resection
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07314554

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteLanzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseEarly detection & endoscopyImaging & AI
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Medical oncologyPathology / laboratory medicine
Papers it led45
  1. Application of machine learning algorithms and establishment of a web calculator in predicting distant metastasis of T2-T4 gastric cancer.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  2. Development of a Machine Learning-Based Predictive Model for Anastomotic Leakage Following Gastric Cancer Surgery.2026The American surgeon
  3. HSPB1 promotes gastric cancer progression by suppressing PANoptosis.2025Acta histochemica
  4. Spectral CT findings of bladder urothelial carcinoma with gastric metastasis: a case report.2025BMC urologyFree full text
  5. Neoadjuvant therapy with immune checkpoint inhibitors in combination with chemotherapy vs . chemotherapy alone in HER2(-) locally advanced gastric cancer: A propensity score-matched cohort study.2025Chinese medical journalFree full text
  6. Robotic versus laparoscopic gastrectomy for gastric cancer in asia: A meta-analysis of short-term outcomes from six randomized controlled trials.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  7. The distinct role of IL-34 and IL-35 in gastric cancer.2025Frontiers in immunologyFree full text
  8. Exploring the possible mechanism of low-dose naloxone exposure improving the immune microenvironment of gastric cancer tumors.2025Frontiers in immunologyFree full text
  9. Serum TFF2 as a more reliable biomarker for gastric cancer and early gastric cancer: a cross-sectional population-based study.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  10. Bioinformatics analysis of the expression of TRIM31 mRNA and protein in pan-cancer tissues and their prognostic relevance.2025Scientific reportsFree full text
  11. Multi-omics analysis identifies LANCL2 as a potential biomarker for the diagnosis and prognosis of gastric cancer.2025Scientific reportsFree full text
  12. Cost-effectiveness of open vs. laparoscopic gastrectomy for locally advanced gastric cancer in China.2025Scientific reportsFree full text
  13. Machine learning-random forest model was used to construct gene signature associated with cuproptosis to predict the prognosis of gastric cancer.2025Scientific reportsFree full text
  14. Causal Effects of Metabolic Syndrome on Gastric Disorders: Univariable and Multivariable Mendelian Randomization.2025The Journal of clinical endocrinology and metabolism
  15. Notch1 signaling pathway promotes growth and metastasis of gastric cancer via modulating CDH5.2024AgingFree full text
  16. The role of THBS1 and PDGFD in the immune microenvironment of Helicobacter pylori-associated gastric cancer.2024Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  17. AKT1-Mediated NOTCH1 phosphorylation promotes gastric cancer progression via targeted regulation of IRS-1 transcription.2024Journal of cancer research and clinical oncologyFree full text
  18. The association between trace metals in both cancerous and non-cancerous tissues with the risk of liver and gastric cancer progression in northwest China.2024Journal of pharmaceutical and biomedical analysis
  19. KPNA2 promotes the progression of gastric cancer by regulating the alternative splicing of related genes.2024Scientific reportsFree full text
  20. Development and validation of a tumor size-stratified prognostic nomogram for patients with gastric signet ring cell carcinoma.2024Updates in surgeryFree full text
  21. Primary squamous cell carcinoma of the stomach with HP infection: A rare case report.2023Asian journal of surgery
  22. Preoperative radiotherapy affects the prognosis of patients with stage T1-3N0-1M0 gastroesophageal junction adenocarcinoma.2023Asian journal of surgery
  23. Dynamic variations of the gastric microbiota: Key therapeutic points in the reversal of Correa's cascade.2023International journal of cancer
  24. Neutrophil elastase as a potential biomarker related to the prognosis of gastric cancer and immune cell infiltration in the tumor immune microenvironment.2023Scientific reportsFree full text
  25. Insulin for hyperglycemia prevention and management during postgastrectomy nutrition support in gastric cancer: Reduced complications in a retrospective cohort study in China.2022Asia Pacific journal of clinical nutritionRCT
  26. The Association of Trefoil Factors with Gastric Cancer and Premalignant Lesions: A Cross-Sectional Population-Based Cohort Study.2022Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  27. Polyphenol Mechanisms against Gastric Cancer and Their Interactions with Gut Microbiota: A Review.2022Current oncology (Toronto, Ont.)Free full text
  28. Knockout of UBE2S inhibits the proliferation of gastric cancer cells and induces apoptosis by FAS-mediated death receptor pathway.2022Experimental cell research
  29. Thiostrepton confers protection against reactive oxygen species-related apoptosis by restraining FOXM1-triggerred development of gastric cancer.2022Free radical biology & medicine
  30. Prognostic biomarker HAMP and associates with immune infiltration in gastric cancer.2022International immunopharmacology
  31. TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR.2022International journal of biological sciencesFree full text
  32. Relationship of vitamin D intake, serum 25(OH) D, and solar ultraviolet-B radiation with the risk of gastric cancer: A meta-analysis.2022Journal of cancer research and therapeutics
  33. Comprehensive analysis to identify DNA damage response-related lncRNA pairs as a prognostic and therapeutic biomarker in gastric cancer.2022Mathematical biosciences and engineering : MBE
  34. Family with sequence similarity 153 member B as a potential prognostic biomarker of gastric cancer.2022Mathematical biosciences and engineering : MBE
  35. Role of annexin A family in tumorigenesis and chemoresistance of gastric cancer.2022Neoplasma
  36. Identification of the RP11-21C4.1/SVEP1 gene pair associated with FAT2 mutations as a potential biomarker in gastric cancer.2021BioengineeredFree full text
  37. Effect of Helicobacter Pylori on Plasma Metabolic Phenotype in Patients With Gastric Cancer.2021Cancer control : journal of the Moffitt Cancer CenterFree full text
  38. Bcl2-associated athanogene 4 promotes the invasion and metastasis of gastric cancer cells by activating the PI3K/AKT/NF-κB/ZEB1 axis.2021Cancer letters
  39. Knockdown of Microtubule Associated Serine/threonine Kinase Like Expression Inhibits Gastric Cancer Cell Growth and Induces Apoptosis by Activation of ERK1/2 and Inactivation of NF-κB Signaling.2021Current medical science
  40. Research on the relationship between RAGE and its ligand HMGB1, and prognosis and pathogenesis of gastric cancer with diabetes mellitus.2021European review for medical and pharmacological sciences
  41. CSMD1 Mutations Are Associated with Increased Mutational Burden, Favorable Prognosis, and Anti-Tumor Immunity in Gastric Cancer.2021GenesFree full text
  42. Prevalence and risk factors of Helicobacter pylori infection in Wuwei, a high-risk area for gastric cancer in northwest China: An all-ages population-based cross-sectional study.2021Helicobacter
  43. Cohort Profile: A population-based cohort for the study of gastric cancer in northwest area of China (Wuwei Cohort).2021International journal of epidemiology
  44. CBX2 depletion inhibits the proliferation, invasion and migration of gastric cancer cells by inactivating the YAP/β-catenin pathway.2021Molecular medicine reportsFree full text
  45. NAT10 promotes gastric cancer metastasis via N4-acetylated COL5A1.2021Signal transduction and targeted therapyFree full text
Chinese-language papers (not in the count)1
  1. [Clinical characteristics and prognosis analysis of gastric cancer patients with bone metastasis].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status13
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. Esomeprazole Plus Sucralfate for Post-ESD Ulcer HealingNot yet recruitingNCT07312370Study sitePhase 4Start 2026-04
  3. Recurrence After Gastric and Intestinal Polyp ResectionNot yet recruitingNCT07314554Study siteStart 2026-07
  4. SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid TumorsRecruitingNCT06873659Study sitePhase 1Start 2025-02
  5. Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06949033Study sitePhase 3Start 2025-05
  6. Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06925243Study sitePhase 3Start 2025-04
  7. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  8. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  9. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  10. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  11. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  12. Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total GastrectomyStatus unknownNCT02110628Study sitePhase 3Start 2014-08
  13. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

8 hospitals in Lanzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Lanzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Lanzhou for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Association of Cytotoxic T-lymphocyte Antigen-4 Polymorphisms with Malignant Bone Tumor Risk: A Meta-analysis.2016Asian Pacific journal of cancer prevention : APJCP

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

3 hospitals in Lanzhou for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesCAR-T & cell therapy
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Lanzhou for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06833983

    Age 18 years to 65 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou

  2. Recruiting
    An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
    Phase
    Phase 1/Phase 2
    Started
    2024-05
    Registry
    NCT07644832

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Hefei, Jinan, Lanzhou, Taiyuan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led1
  1. Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients.2022Haemophilia : the official journal of the World Federation of HemophiliaRCT
Earlier papers (2016–2020)1
  1. [Clinical Characteristics of 223 Chinese Patients with Hemophilia in A Medical Center of Gansu Province in China].2016Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status9
  1. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia ARecruitingNCT06833983Study sitePhase 3Start 2025-03
  2. An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII DeficiencyRecruitingNCT07644832Study sitePhase 1/Phase 2Start 2024-05
  3. A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia AActive, not recruitingNCT06297655Study sitePhase 3Start 2024-11
  4. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  5. Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With InhibitorStatus unknownNCT05487976Study sitePhase 3Start 2022-04
  6. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia ACompletedNCT04845399Study sitePhase 3Start 2021-04
  7. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.CompletedNCT04456387Study sitePhase 3Start 2020-10
  8. Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.Status unknownNCT04061109Study sitePhase 3Start 2019-05
  9. Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.Status unknownNCT04060836Study sitePhase 1Start 2019-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led 1 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Lanzhou for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Lanzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Kisspeptin‑13 inhibits bleomycin‑induced pulmonary fibrosis through GPR54 in mice.2019Molecular medicine reports

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Lanzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy AdultsEnrolling by invitationNCT06782958Study sitePhase 1Start 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Lanzhou for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Lanzhou for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Lanzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  2. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Lanzhou for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Lanzhou for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Papers it led1
  1. Role of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value.2022World journal of gastroenterology
Earlier papers (2016–2020)1
  1. Dramatic imaging changes of a biliary stricture within 8 months in a rare case.2020The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Lanzhou for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Phase 2 in Adult Subjects With Hereditary AngioedemaActive, not recruitingNCT06846398Study sitePhase 2Start 2025-02

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

兰州大学第一医院

First Hospital of Lanzhou University

兰州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
First Hospital of LanZhou University; Donggang Branch of First Hospital of Lanzhou University; Donggang Branch of The First Hospital of Lanzhou University; Donggang District of First Hospital of Lanzhou University; 兰州大学第一医院: 欢迎您| 兰大一院

Suggest a correctionDownload the data